PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD 725.00
-3.00 (-0.41%)
Feb 11, 2026, 1:30 PM CST
PharmaEssentia Revenue
PharmaEssentia had revenue of 3.89B TWD in the quarter ending September 30, 2025, with 43.50% growth. This brings the company's revenue in the last twelve months to 13.82B, up 66.04% year-over-year. In the year 2024, PharmaEssentia had annual revenue of 9.73B with 90.67% growth.
Revenue (ttm)
13.82B
Revenue Growth
+66.04%
P/S Ratio
19.41
Revenue / Employee
105.46M
Employees
131
Market Cap
268.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | 557.26M | 251.57M | 82.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| Grape King Bio | 10.40B |
| YungShin Global Holding | 8.37B |
| TTY Biopharm Company | 6.50B |
| Synmosa Biopharma | 6.11B |
| ScinoPharm Taiwan | 3.19B |
| Handa Pharmaceuticals | 1.62B |
PharmaEssentia News
- 4 weeks ago - PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft - Nasdaq
- 1 year ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga